Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction

Journal of Physiology

Volumn 574, Issue 2, 2006, Pages 615-626

  Houweling, Birgit ^a   Merkus, Daphne ^a   Sorop, Oana ^a   Boomsma, Frans ^b   Duncker, Dirk J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EMD 122946; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; TEZOSENTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; HEART INFARCTION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REST; SWINE; TREADMILL EXERCISE; VASOCONSTRICTION; WAKEFULNESS; ANIMAL TISSUE; FEMALE; LUNG CIRCULATION; LUNG VASOCONSTRICTION; MALE;

ANIMALS; BLOOD PRESSURE; CONSCIOUSNESS; ENDOTHELIN-1; FEMALE; HEMODYNAMIC PROCESSES; HYPERTENSION, PULMONARY; MALE; MYOCARDIAL INFARCTION; PHYSICAL CONDITIONING, ANIMAL; PULMONARY CIRCULATION; PYRIDINES; RECEPTORS, ENDOTHELIN; REST; SWINE; TETRAZOLES; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 33745858682     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.107060     Document Type: Article

References (52)

1. Ahmed SI, Thompson J, Coulson JM & Woll PJ (2000). Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22, 422-431.
2. Alonso D & Radomski MW (2003). The nitric oxide-endothelin-1 connection. Heart Fail Rev 8, 107-115.
3. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S et al. (2004). Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169, 441-447.
4. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F & Rubin LJ (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 358, 1119-1123.
5. Cleland JG, Coletta AP, Lammiman M, Witte KK, Loh H, Nasir M & Clark AL (2005). Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail 7, 1070-1075.
6. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM, Coassolo P & Roux S (1999). Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290, 840-846.
7. Cody RJ, Haas GJ, Binkley PF, Capers Q & Kelley R (1992). Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85, 504-509.
8. Colucci WS & Braunwald E (2001). Pathophysiology of heart failure. In Heart Disease - a Textbook of Cardiovascular Medicine, vol. 1, ed. Braunwald E, Zipes DP & Libby P, pp. 503-534. W.B. Saunders Company, Philadelphia.
9. Docherty CC & MacLean MR (1998). Endothelin-B receptors in rabbit pulmonary resistance arteries: Effect of left ventricular dysfunction. J Pharmacol Exp Ther 284, 895-903.
10. + ATP channels in regulation of systemic, pulmonary, and coronary vasomotor tone in exercising swine. Am J Physiol Heart Circ Physiol 280, H22-H33.
11. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, Bonan R & Crepeau J (1998 a). Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 135, 614-620.
12. Dupuis J, Goresky CA & Stewart DJ (1994). Pulmonary removal and production of endothelin in the anesthetized dog. J Appl Physiol 76, 694-700.
13. Dupuis J, Rouleau JL & Cernacek P (1998 b). Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 98, 1684-1687.
14. Dupuis J, Stewart DJ, Cernacek P & Gosselin G (1996). Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94, 1578-1584.
15. Ergul A, Grubbs AL, Zhang Y, Joffs C, Sample JA, King MK & Spinale FG (2001). Expression and activity of pulmonary endothelin converting enzyme in heart failure: Relation to endothelin biosynthesis and receptor distribution. J Card Fail 7, 84-91.
16. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M & Nishikibe M (1994). Clearance of circulating endothelin-1 by ET B receptors in rats. Biochem Biophys Res Commun 199, 1461-1465.
17. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM et al. (2005). Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46, 529-535.
18. Galie N, Manes A & Branzi A (2004). The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61, 227-237.
19. Goldie RG (1998). Endothelin receptor subtypes: Distribution and function in the lung. Pulm Pharmacol Ther 11, 89-95.
20. Guarracino F, Cariello C, Danella A, Doroni L, Lapolla F, Vullo C, Pasquini C & Stefani M (2005). Right ventricular failure: Physiology and assessment. Minerva Anestesiol 71, 307-312.
21. Haitsma DB, Bac D, Raja N, Boomsma F, Verdouw PD & Duncker DJ (2001). Minimal impairment of myocardial blood flow responses to exercise in the remodeled left ventricle early after myocardial infarction, despite significant hemodynamic and neurohumoral alterations. Cardiovasc Res 52, 417-428.
22. Haitsma DB, Merkus D, Vermeulen J, Verdouw PD & Duncker DJ (2002). Nitric oxide production is maintained in exercising swine with chronic left ventricular dysfunction. Am J Physiol Heart Circ Physiol 282, H2198-H2209.
23. Houweling B, Merkus D, Dekker MM & Duncker DJ (2005). Nitric oxide blunts the endothelin-mediated pulmonary vasoconstriction in exercising swine. J Physiol 568, 629-638.
24. Ivy DD, Le Cras TD, Horan MP & Abman SH (1998). Increased lung preproET-1 and decreased ET B-receptor gene expression in fetal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 274, L535-L541.
25. Kelly LK, Wedgwood S, Steinhorn RH & Black SM (2004). Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol Lung Cell Mol Physiol 286, L984-L991.
26. Kjekshus H, Smiseth OA, Klinge R, Oie E, Hystad ME & Attramadal H (2000). Regulation of ET: Pulmonary release of ET contributes to increased plasma ET levels and vasoconstriction in CHF. Am J Physiol Heart Circ Physiol 278, H1299-H1310.
27. Kobayshi T, Miyauchi T, Sakai S, Maeda S, Yamaguchi I, Goto K & Sugishita Y (1998). Down-regulation of ET B receptor, but not ET A receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1?Life Sci 62, 185-193.
28. Langleben D, Brock T, Dixon R & Barst R (2004). STRIDE 1: Effects of the selective ET A receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 44, S80-S84.
29. Lavallee M, Takamura M, Parent R & Thorin E (2001). Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 6, 265-276.
30. Lepailleur-Enouf D, Egidy G, Philippe M, Louedec L, Henry J, Mulder P & Michel J (2001). Pulmonary endothelinergic system in experimental congestive heart failure. Cardiovasc Res 49, 330-339.
31. B-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 23, 838-845.
32. Mederski WW, Dorsch D, Osswald M, Anzali S, Christadler M, Schmitges CJ, Schelling P, Wilm C & Fluck M (1998). Endothelin antagonists: discovery of EMD 122946, a highly potent and orally active ET A selective antagonist. Bioorg Med Chem Lett 8, 1771-1776.
33. Merkus D, Houweling B, Mirza A, Boomsma F, van den Meiracker AH & Duncker DJ (2003). Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation. Cardiovasc Res 59, 745-754.
34. Merkus D, Houweling B, van den Meiracker AH, Boomsma F & Duncker DJ (2005). Contribution of endothelin to coronary vasomotor tone is abolished after myocardial infarction. Am J Physiol Heart Circ Physiol 288, H871-H880.
35. Moraes DL, Colucci WS & Givertz MM (2000). Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management. Circulation 102, 1718-1723.
36. Motte S, McEntee K & Naeije R (2006). Endothelin receptor antagonists. Pharmacol Ther 110 (3), 386-414.
37. Nauser TD & Stites SW (2001). Diagnosis and treatment of pulmonary hypertension. Am Fam Physician 63, 1789-1798.
38. Perreault T & Baribeau J (1995). Characterization of endothelin receptors in newborn piglet lung. Am J Physiol Lung Cell Mol Physiol 268, L607-L614.
39. Remetz MS, Cleman MW & Cabin HS (1989). Pulmonary and pleural complications of cardiac disease. Clin Chest Med 10, 545-592.
40. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M & Simonneau G (2002). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346, 896-903.
41. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K & Sugishita Y (1996). Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol 28, 1580-1588.
42. Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, Barnes PJ & Giaid A (1997). Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 16, 187-193.
43. Soma S, Takahashi H, Muramatsu M, Oka M & Fukuchi Y (1999). Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol 20, 620-630.
44. Staniloae C, Dupuis J, White M, Gosselin G, Dyrda I, Bois M, Crepeau J, Bonan R, Caron A & Lavoie J (2004). Reduced pulmonary clearance of endothelin in congestive heart failure: A marker of secondary pulmonary hypertension. J Card Fail 10, 427-432.
45. 2 delivery and utilization in swine during treadmill exercise. Cardiovasc Res 39, 459-474.
46. Tadano K, Hosokawa A, Fukuroda T & Nishikibe M (2004). The functional shift of endothelin receptor subtypes in dogs with heart failure produced by rapid ventricular pacing. J Cardiovasc Pharmacol 44 (Suppl. 1), S350-S353.
47. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, Nakajima J, Yanagisawa M & Ito K (1998). Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J 12, 57-63.
48. Tonnessen T, Lunde PK, Giaid A, Sejersted OM & Christensen G (1998). Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin-1 mRNA and endothelin peptide. Cardiovasc Res 39, 633-643.
49. Van der Velden J, Merkus D, Klarenbeek BR, James AT, BoontJe NM. Dekkers DH, Stienen GJ, Lamers JM & Duncker DJ (2004). Alterations in myofilament function contribute to left ventricular dysfunction in pigs early after myocardial infarction. Circ Res 95, e85-95.
50. van Kats JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R, Stubenitsky R, Boomsma F, Schalekamp MA, Verdouw PD & Danser AH (2000). Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: Role of tissue angiotensin II. Circulation 102, 1556-1563.
51. von Lueder TG, Kjekshus H, Edvardsen TEOI, Urheim S, Vinge LE, Ahmed MS, Smiseth OA & Attramadal H (2004). Mechanisms of elevated plasma endothelin-1 in CHF: Congestion increases pulmonary synthesis and secretion of endothelin-1. Cardiovasc Res 63, 41-50.
52. Yap EY, Battistini B & McKay KO (2000). Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi. Br J Pharmacol 129, 170-176.